IRVINE, Calif.--(BUSINESS WIRE)--Cobalis Corp. (OTCBB:CLSC), a pharmaceutical company specializing in anti-allergy medications, today reported that seasonal allergy patients who received PreHistin had on average less ragweed IgE after the treatment than those who received placebo.
This is important because IgE is a key chemical mediator in allergic reactions. Developing a drug that can safely reduce specific IgE levels is a goal of drug companies.
